Life Science Investing BioRestorative Awarded Notice of Allowance for Japanese Patent - Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market
Life Science Investing BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio
Life Science Investing BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market
Life Science Investing BioRestorative Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update
Nextech3D.ai Reports Strong 20% Q2 Sequential Revenue Growth With Gross Margins of 88% For the Three Months Ended September 30, 2025 ("Q2 2026")
